Immunomedics, Inc., (NASDAQ:IMMU) has confirmed its participation in the 26th Annual Oppenheimer Health Conference led by analysts. A few days back the biopharmaceutical company had announced that it would present the results of its proprietary anti-HLA-DR antibody on the IMMU-114 at the American Society of Hematology’s 57th Annual Meeting.
The clinical trial is in its first phase and is being carried out for the patients with hematological cancers. The result is expected to reveal the convenient and safe subcutaneous administration in the patients showing the first evidence of the disease.
Creating Humanized Antibodies
Immunomedics develops monoclonal products based on the antibody that are targeted towards treating cancer and several other serious and autoimmune diseases. The advanced proprietary technologies of the company allow it to create humanized antibodies that can be easily used in a naked or unlabeled form or as cytokines or toxins, conjugated with radioactive isotopes or as a chemotherapeutic. Over the years, the company has managed to build up a trail of a pipeline with nine clinical-stage product.
Investigational Product Portfolio
90Y-clivatuzumab tetraxetan is the most advanced product from the company. It is a type of radiolabeled antibody and at present is undergoing Phase 3 registration in patients suffering from pancreatic cancer at an advanced stage. The enrollment of patients is expected to be completed by the turn of New Year.
The investigational product portfolio of Immunomedics includes exclusive antibody-drug conjugates (ADCs) designed especially to deliver a dose of chemotherapeutic directly to the malignant tumor. By doing so, it cuts down the overall toxic side effect that is usually associated with the administration of conventional chemotherapeutic medications.
The company also has some of the most advanced ADCs undergoing Phase 2 trials for several metastatic colorectal cancer and solid tumors. These drugs include labetuzumab govitecan (IMMU-130) and sacituzumab govitecan (IMMU-132). The company carries out its research in collaboration with Bayer, and the two are together involved in the study of epratuzumab as a thorium -227-labeled antibody.
Immunomedics, Inc., (NASDAQ:IMMU) also has other collaborations in oncology going on with other independent cancer study groups.